BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 25527786)

  • 21. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
    Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
    J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. After Bone Marrow Transplantation, the Cell-Intrinsic Th2 Pathway Promotes Recipient T Lymphocyte Survival and Regulates Graft-versus-Host Disease.
    Truscott J; Guan X; Fury H; Atagozli T; Metwali A; Liu W; Li Y; Li RW; Elliott DE; Blazar BR; Ince MN
    Immunohorizons; 2023 Jun; 7(6):442-455. PubMed ID: 37294277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
    Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
    Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
    Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
    J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Xing S; Zhang X; Liu JH; Huang X; Zhou P
    Clin Exp Immunol; 2019 Jan; 195(1):121-131. PubMed ID: 30317551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.
    van der Merwe M; Abdelsamed HA; Seth A; Ong T; Vogel P; Pillai AB
    J Immunol; 2013 Dec; 191(11):5764-76. PubMed ID: 24190658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
    Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
    Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
    Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
    Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice.
    Drobyski WR; Vodanovic-Jankovic S; Klein J
    J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.